Ivexsol Stable Viral Vector, EP4150097A1
Summary
Ivexsol, Inc. has been granted European Patent EP4150097A1 for compositions and methods of producing stable viral vector producer cells used in cell and gene therapy. The patent names Michael Greene as the sole inventor and covers viral vector technology intended to improve stability in cell and gene therapy manufacturing. The patent application designated multiple European states including Germany, France, the United Kingdom, and other EU member states.
About this source
GovPing monitors EPO Patent Bulletin - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 61 changes logged to date.
What changed
The European Patent Office has published Patent EP4150097A1, granting Ivexsol, Inc. exclusive rights to compositions and methods for producing stable viral vector producer cells for cell and gene therapy applications. The patent, filed with IPC classifications C12N 15/64 and C12N 15/86, designates multiple European Contracting States including Germany, France, Italy, the Netherlands, Spain, and the United Kingdom among others.
For biotechnology and gene therapy companies developing viral vector-based therapies, this patent establishes intellectual property that may affect freedom-to-operate considerations. Companies engaged in viral vector manufacturing processes for cell and gene therapy should review this granted patent to assess potential licensing implications or design-around options for their own manufacturing methods.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR PRODUCING STABLE VIRAL VECTOR PRODUCER CELLS FOR CELL AND GENE THERAPY
Publication EP4150097A1 Kind: A1 Apr 15, 2026
Applicants
Ivexsol, Inc.
Inventors
GREENE, Michael
IPC Classifications
C12N 15/64 20060101AFI20211119BHEP C12N 15/86 20060101ALI20211119BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.